Kossel Medical Completes Nearly RMB 100 Million Series B+ Financing to Accelerate Global Expansion and Platform Development

Recently, Kossel Medtech (Suzhou) Co., Ltd. ("Kossel Medtech") announced the completion of a nearly RMB 100 million Series B+ financing round. This round was led by Nanjing Railway Investment Jushi Hub Economic Industry Investment Fund Partnership(L.P.), with continued additional investment from SND Finance Control, and participation from Yuan Yong Investment. The funds will be used for core product research and development, global market promotion, and production capacity expansion. This financing round demonstrates investors' full recognition of Kossel Medtech’s rapid and high-quality development and future potential, and also lays a solid foundation for Kossel Medtech to strengthen its platform-based layout.

Kossel Medtech was founded in 2013 and is located in Suzhou, Jiangsu. The company has become a platform enterprise in the field of vascular interventional devices, forming a "one core, three wings" business layout: the parent company builds a "one-stop" treatment system for peripheral interventions (covering venous/arterial); its subsidiary Haiyu Xincheng focuses on the cardiac electrophysiology field (providing comprehensive solutions for treating tachyarrhythmia); its subsidiary Mixin Medtech concentrates on the research and development of coronary intervention products and the transfer of overseas technologies; its subsidiary Haiwang Medtech is committed to breaking through the "bottleneck" technology of medical core raw materials.